Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Corporate Action-Board to consider Dividend

 With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday, 6th March, 2020 to inter-alia consider declaration of Interim Dividend, if any, on the Equity Shares of the Company, for the financial year 2019-20. Further, pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company will be closed from 26th February, 2020 and will re-open 48 hours after the conclusion of the Board Meeting. We request you to kindly take the same on record.
25-02-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Corporate Action-Board to consider Dividend

 With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday, 6th March, 2020 to inter-alia consider declaration of Interim Dividend, if any, on the Equity Shares of the Company, for the financial year 2019-20. Further, pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company will be closed from 26th February, 2020 and will re-open 48 hours after the conclusion of the Board Meeting. We request you to kindly take the same on record.
25-02-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window

 With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday, 6th March, 2020 to inter-alia consider declaration of Interim Dividend, if any, on the Equity Shares of the Company, for the financial year 2019-20. Further, pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company will be closed from 26th February, 2020 and will re-open 48 hours after the conclusion of the Board Meeting. We request you to kindly take the same on record.
25-02-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for To Consider Declaration Of Interim Dividend

 ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/03/2020 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday, 6th March, 2020 to inter-alia consider declaration of Interim Dividend, if any, on the Equity Shares of the Company, for the financial year 2019-20. Further, pursuant to the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company will be closed from 26th February, 2020 and will re-open 48 hours after the conclusion of the Board Meeting. We request you to kindly take the same on record.
25-02-2020
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) and / or legal heir(s) of the registered shareholders have requested the Company for issue of duplicate share certificate(s).
20-02-2020
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal heir(s) of the registered shareholders on 20th February, 2020.
20-02-2020
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 20th February, 2020. We request you to kindly take the same on record.
20-02-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s).
05-02-2020
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Re-Appointment Of Independent Director

 With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee and the Board of Directors, the shareholders of the Company at their 9th Annual General Meeting held on 29th July, 2019 had approved by way of special resolution, the re-appointment of Dr. Archana Hingorani as an Independent Director of the Company for her second term of five consecutive years w.e.f. 4th February, 2020. The proceedings of the aforesaid Annual General Meeting was submitted with the exchange on 29th July, 2019. Dr. Archana Hingorani is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 is enclosed herewith as Annexure - A. We request you to kindly take the same on record.
04-02-2020
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Approval for Clobetasol Propionate Cream USP, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
29-01-2020
Next Page
Close

Let's Open Free Demat Account